We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Seagen Inc (SGEN) USD0.001

Sell:$127.55 Buy:$127.79 Change: $5.51 (4.14%)
Market closed |  Prices as at close on 21 January 2022 | Switch to live prices |
Change: $5.51 (4.14%)
Market closed |  Prices as at close on 21 January 2022 | Switch to live prices |
Change: $5.51 (4.14%)
Market closed |  Prices as at close on 21 January 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Seagen Inc. is a biotechnology company that develops and commercializes targeted therapies to treat cancer. The Company is engaged in the development and sale of pharmaceutical products on its own, behalf or in collaboration with others. The Company is commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, and TUKYSA, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. The Company also develops a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs. Its programs, including ADCETRIS and PADCEV, are based on its antibody-drug conjugate (ADC), technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The Company's approved medicines include ADCETRIS, PADCEV and TUKYSA.

Contact details

21823 30Th Drive Se, Suite
United States
+1 (425) 5274000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$24.24 billion
Shares in issue:
182.86 million
United States
US dollar

Key personnel

  • Clay Siegall
    Chairman of the Board, President, Chief Executive Officer
  • Todd Simpson
    Chief Financial Officer
  • Jean Liu
    Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary
  • Chip Romp
    Executive Vice President - Commercial U.S.
  • Vaughn Himes
    Chief Technical Officer
  • Roger Dansey
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.